C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 6.1 HKD
Market Cap: 2.2B HKD

Cutia Therapeutics
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cutia Therapeutics
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
C
Cutia Therapeutics
HKEX:2487
EPS (Diluted)
-ÂĄ1
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
EPS (Diluted)
-ÂĄ3
CAGR 3-Years
21%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
EPS (Diluted)
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
EPS (Diluted)
ÂĄ0
CAGR 3-Years
23%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
EPS (Diluted)
ÂĄ0
CAGR 3-Years
15%
CAGR 5-Years
14%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
EPS (Diluted)
-ÂĄ1
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cutia Therapeutics
Glance View

Market Cap
2.2B HKD
Industry
Biotechnology

Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.

Intrinsic Value
13.67 HKD
Undervaluation 55%
Intrinsic Value
Price
C

See Also

What is Cutia Therapeutics's EPS (Diluted)?
EPS (Diluted)
-1.4 CNY

Based on the financial report for Dec 31, 2024, Cutia Therapeutics's EPS (Diluted) amounts to -1.4 CNY.

What is Cutia Therapeutics's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-10%

Over the last year, the EPS (Diluted) growth was 78%. The average annual EPS (Diluted) growth rates for Cutia Therapeutics have been -10% over the past three years .

Back to Top